0000000000188474

AUTHOR

Juan J. Badimon

showing 2 related works from this author

Mortality associated with cardiovascular disease in patients with COVID-19

2020

Introducción y objetivos: Las enfermedades cardiovasculares (ECV) se han identificado como un factor de riesgo de mal pronóstico en pacientes con infección por COVID-19. Métodos: Se realizó un metanálisis de estudios actualmente disponibles con la prevalencia de ECV en supervivientes frente a no supervivientes en pacientes con infección por COVID-19 hasta el 16 de julio de 2020. Los análisis se realizaron mediante un modelo de efectos aleatorios y sensibilidad. Se realizaron análisis para identificar posibles fuentes de heterogeneidad o evaluar los efectos de los estudios pequeños. Resultados: Se incluyó a 307.596 pacientes de 16 estudios, de los que 46.321 (15,1%) tenían ECV. La tasa de mo…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryMortality rateEnfermedad cardiovascularCOVID-19DiseaseCardiovascular diseasemedicine.diseaseRandom effects modelArticleCoronavirusCVD cardiovascular deseaseInternal medicineDiabetes mellitusMortalidadmedicineRisk of mortalityIn patientMortalityRisk factorCardiology and Cardiovascular MedicinebusinessREC: CardioClinics
researchProduct

Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions

2008

Nanoparticle contrast agents for MRI may aid in identifying atherosclerotic lesions that give rise to ischemic events by means of penetration and retention in the plaque. These imaging agents may provide valuable information regarding plaque characteristics which can help determine the risk of plaque rupture. By increasing molecular flexibility or adding a means of specifically targeting ligands via antibody or peptide, nanoparticles can enhance certain regions of the atherosclerotic plaque. The development of single contrast agents detectable with multiple imaging modalities may further improve our ability to detect and characterize atherosclerosis in clinical and preclinical applications.…

lcsh:Diseases of the circulatory (Cardiovascular) systembusiness.industryPlaque ruptureClinical scienceBioinformaticsOriginal researchImaging modalitieslcsh:RC666-701Drug deliverySingle contrastMedicineCancer geneCardiology and Cardiovascular MedicinebusinessTargeting ligandsClinical medicine. Cardiology
researchProduct